AR040887A1 - Formulacion y metodo de complejo de aripiprazol - Google Patents
Formulacion y metodo de complejo de aripiprazolInfo
- Publication number
- AR040887A1 AR040887A1 AR20030102990A ARP030102990A AR040887A1 AR 040887 A1 AR040887 A1 AR 040887A1 AR 20030102990 A AR20030102990 A AR 20030102990A AR P030102990 A ARP030102990 A AR P030102990A AR 040887 A1 AR040887 A1 AR 040887A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- complex
- aripiprazol
- aripiprazole
- cyclodextrin
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960004372 aripiprazole Drugs 0.000 abstract 2
- 238000010255 intramuscular injection Methods 0.000 abstract 2
- 239000007927 intramuscular injection Substances 0.000 abstract 2
- 230000007794 irritation Effects 0.000 abstract 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulación de aripiprazol que incluye un agente antimicótico en la forma de un complejo de inclusión en una beta-ciclodextrina, preferiblemente beta-ciclodextrina de éter sulfobutilo (SBECD), que en la forma de un inyectable produce generalmente reversible irritación mínima a moderada en el sitio de inyección intramuscular. Método para minimizar a reducir la irritación causada por el aripiprazol en un sitio de inyección intramuscular y un método para tratar esquizofrenia mediante el empleo de la formulación anterior.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40471302P | 2002-08-20 | 2002-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040887A1 true AR040887A1 (es) | 2005-04-20 |
Family
ID=31946748
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102990A AR040887A1 (es) | 2002-08-20 | 2003-08-19 | Formulacion y metodo de complejo de aripiprazol |
| ARP150103114A AR102101A2 (es) | 2002-08-20 | 2015-09-28 | Formulación y método de complejo de aripiprazol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103114A AR102101A2 (es) | 2002-08-20 | 2015-09-28 | Formulación y método de complejo de aripiprazol |
Country Status (32)
| Country | Link |
|---|---|
| US (8) | US7115587B2 (es) |
| EP (1) | EP1542668B1 (es) |
| JP (1) | JP4729306B2 (es) |
| KR (1) | KR101043866B1 (es) |
| CN (1) | CN100335047C (es) |
| AR (2) | AR040887A1 (es) |
| AT (1) | ATE428423T1 (es) |
| AU (1) | AU2003269965B2 (es) |
| BR (1) | BR0313602A (es) |
| CA (1) | CA2495864C (es) |
| CY (1) | CY1110331T1 (es) |
| DE (1) | DE60327225D1 (es) |
| DK (1) | DK1542668T3 (es) |
| ES (1) | ES2322953T3 (es) |
| GE (1) | GEP20063996B (es) |
| HR (1) | HRP20050149B1 (es) |
| IL (1) | IL166623A (es) |
| IS (1) | IS2878B (es) |
| MX (1) | MXPA05001865A (es) |
| MY (1) | MY140793A (es) |
| NO (1) | NO333458B1 (es) |
| NZ (1) | NZ537995A (es) |
| PE (1) | PE20040895A1 (es) |
| PL (1) | PL212428B1 (es) |
| PT (1) | PT1542668E (es) |
| RS (1) | RS51903B (es) |
| RU (1) | RU2342931C2 (es) |
| SI (1) | SI1542668T1 (es) |
| TW (1) | TWI307626B (es) |
| UA (1) | UA79984C2 (es) |
| WO (1) | WO2004017897A2 (es) |
| ZA (1) | ZA200501064B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040170705A1 (en) * | 2001-03-08 | 2004-09-02 | Dusan Miljkovic | Compositions and methods for non-insulin glucose uptake |
| SI1542668T1 (sl) * | 2002-08-20 | 2009-08-31 | Bristol Myers Squibb Co | Aripiprazol sestavljena formulacija in postopek |
| CN1870980B (zh) | 2003-10-23 | 2010-06-23 | 大冢制药株式会社 | 控释无菌阿立哌唑注射剂和方法 |
| US7714129B2 (en) | 2003-12-16 | 2010-05-11 | Teva Pharmaceutical Industries Ltd. | Methods of preparing anhydrous aripiprazole form II |
| PL1613598T3 (pl) * | 2003-12-16 | 2012-03-30 | Teva Pharma | Sposób wytwarzania krystalicznych form aripiprazolu |
| UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
| US20090252807A1 (en) * | 2005-04-13 | 2009-10-08 | Elan Pharma International Limited | Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives |
| ATE459341T1 (de) * | 2005-06-03 | 2010-03-15 | Elan Pharma Int Ltd | Nanoteilchenförmige imatinib-mesylat- formulierungen |
| CA2611917A1 (en) * | 2005-06-13 | 2006-12-21 | Takeda Pharmaceutical Company Limited | Injection |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| EP1959966B1 (en) | 2005-11-28 | 2020-06-03 | Marinus Pharmaceuticals, Inc. | Ganaxolone formulations and methods for the making and use thereof |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| CN101322709B (zh) * | 2007-06-12 | 2011-03-02 | 成都康弘药业集团股份有限公司 | 一种含有阿立哌唑的药物组合物及其制备方法 |
| BRPI0815382A2 (pt) | 2007-07-31 | 2015-02-10 | Otsuka Pharma Co Ltd | Métodos para a produção de suspensão de aripiprazol e formulação de secagem por congelamento |
| WO2009048947A1 (en) * | 2007-10-09 | 2009-04-16 | Board Of Regents, The University Of Texas System | Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors |
| MX2010009848A (es) * | 2008-03-21 | 2010-09-30 | Elan Pharma Int Ltd | Composiciones para el suministro especifico en sitio de imatinib y metodos de uso. |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| EP2445343B1 (en) | 2009-06-25 | 2021-08-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| AU2010266018B2 (en) | 2009-06-25 | 2014-01-09 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| WO2011023796A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Healthcare Products B.V. | Bifeprunox for treating addiction |
| KR101125210B1 (ko) * | 2009-09-11 | 2012-03-19 | 주식회사 대웅제약 | 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법 |
| US20110140304A1 (en) * | 2009-12-10 | 2011-06-16 | Molecular Imprints, Inc. | Imprint lithography template |
| NZ604423A (en) | 2010-06-24 | 2015-01-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| US8383663B2 (en) * | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| EP4327872A3 (en) | 2011-03-18 | 2024-07-10 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
| US8969337B2 (en) | 2011-12-15 | 2015-03-03 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
| TW201332572A (zh) * | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β－環糊精之藥物製劑 |
| DK3702374T3 (da) | 2012-02-15 | 2022-06-27 | Cydex Pharmaceuticals Inc | Fremsgangsmåde til fremstilling for cyclodextrin-derivater |
| NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
| ES2764383T3 (es) | 2012-03-19 | 2020-06-03 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de glicerol |
| NZ630428A (en) | 2012-03-19 | 2017-02-24 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising benzyl alcohol |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| KR101571670B1 (ko) | 2012-08-08 | 2015-11-25 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제 |
| CA2885196C (en) | 2012-09-19 | 2021-06-22 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
| GR1008186B (el) | 2013-04-22 | 2014-05-08 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| JP6203682B2 (ja) * | 2013-07-10 | 2017-09-27 | 共和薬品工業株式会社 | アリピプラゾール含有水性液剤 |
| US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| US20150086408A1 (en) * | 2013-09-26 | 2015-03-26 | General Electric Company | Method of manufacturing a component and thermal management process |
| TW202348234A (zh) | 2013-12-24 | 2023-12-16 | 維吉尼亞聯邦大學 | 氧化膽固醇硫酸鹽（ｏｃｓ）之用途 |
| GR1008442B (el) | 2014-01-16 | 2015-03-05 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης |
| WO2015143145A1 (en) | 2014-03-20 | 2015-09-24 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| CN105078910B (zh) * | 2015-09-22 | 2018-05-22 | 成都欣捷高新技术开发有限公司 | 一种含有依匹哌唑的冻干口服制剂及其制备方法 |
| CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| CN105616344A (zh) * | 2016-01-06 | 2016-06-01 | 万全万特制药江苏有限公司 | 阿立哌唑注射液及其制备方法 |
| HRP20220932T1 (hr) * | 2016-08-02 | 2022-10-28 | Virginia Commonwealth University | Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid |
| AU2017311412B2 (en) | 2016-08-11 | 2023-05-18 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| JP2019535722A (ja) | 2016-11-18 | 2019-12-12 | アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾シクロデキストリン及び酸性化剤に基づくアミジン置換ベータ−ラクタム化合物の新規製剤、それらの製造及び抗菌医薬組成物としての使用 |
| JP6603815B2 (ja) * | 2017-11-21 | 2019-11-06 | 積水化学工業株式会社 | 皮膚外用剤 |
| US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| CA3158280A1 (en) | 2019-12-06 | 2021-06-10 | Alex Aimetti | Ganaxolone for use in treating tuberous sclerosis complex |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP2893175B2 (ja) * | 1988-10-31 | 1999-05-17 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
| JPH07165616A (ja) * | 1993-12-09 | 1995-06-27 | Hisamitsu Pharmaceut Co Inc | シクロデキストリンの複合組成物及び複合化法 |
| US5646131A (en) | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| IT1269578B (it) | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
| UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| JP4012994B2 (ja) * | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
| JPH10194996A (ja) | 1996-12-25 | 1998-07-28 | Janssen Pharmaceut Nv | アシル化シクロデキストリン含有製薬組成物 |
| GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
| GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| SE0200301D0 (sv) | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
| SI1542668T1 (sl) * | 2002-08-20 | 2009-08-31 | Bristol Myers Squibb Co | Aripiprazol sestavljena formulacija in postopek |
| WO2004037224A1 (en) | 2002-10-25 | 2004-05-06 | Pfizer Products Inc. | Depot formulations of arylheterocyclic active agents in the form of a suspension |
-
2003
- 2003-08-14 SI SI200331586T patent/SI1542668T1/sl unknown
- 2003-08-14 JP JP2004531017A patent/JP4729306B2/ja not_active Expired - Fee Related
- 2003-08-14 NZ NZ537995A patent/NZ537995A/en not_active IP Right Cessation
- 2003-08-14 AU AU2003269965A patent/AU2003269965B2/en not_active Ceased
- 2003-08-14 RS YU20050118A patent/RS51903B/sr unknown
- 2003-08-14 PT PT03751859T patent/PT1542668E/pt unknown
- 2003-08-14 CA CA2495864A patent/CA2495864C/en not_active Expired - Fee Related
- 2003-08-14 DE DE60327225T patent/DE60327225D1/de not_active Expired - Lifetime
- 2003-08-14 PL PL374798A patent/PL212428B1/pl unknown
- 2003-08-14 WO PCT/US2003/025573 patent/WO2004017897A2/en active Application Filing
- 2003-08-14 ES ES03751859T patent/ES2322953T3/es not_active Expired - Lifetime
- 2003-08-14 TW TW092122407A patent/TWI307626B/zh not_active IP Right Cessation
- 2003-08-14 GE GEAP8703A patent/GEP20063996B/en unknown
- 2003-08-14 DK DK03751859T patent/DK1542668T3/da active
- 2003-08-14 US US10/642,366 patent/US7115587B2/en not_active Expired - Lifetime
- 2003-08-14 AT AT03751859T patent/ATE428423T1/de active
- 2003-08-14 EP EP03751859A patent/EP1542668B1/en not_active Expired - Lifetime
- 2003-08-14 BR BR0313602-7A patent/BR0313602A/pt not_active Application Discontinuation
- 2003-08-14 RU RU2005107471/15A patent/RU2342931C2/ru not_active IP Right Cessation
- 2003-08-14 KR KR1020057002789A patent/KR101043866B1/ko active IP Right Grant
- 2003-08-14 UA UAA200502492A patent/UA79984C2/uk unknown
- 2003-08-14 CN CNB038195534A patent/CN100335047C/zh not_active Expired - Fee Related
- 2003-08-14 MX MXPA05001865A patent/MXPA05001865A/es active IP Right Grant
- 2003-08-15 MY MYPI20033103A patent/MY140793A/en unknown
- 2003-08-19 AR AR20030102990A patent/AR040887A1/es not_active Application Discontinuation
- 2003-08-20 PE PE2003000843A patent/PE20040895A1/es not_active Application Discontinuation
-
2005
- 2005-02-01 IL IL166623A patent/IL166623A/en active IP Right Grant
- 2005-02-04 ZA ZA200501064A patent/ZA200501064B/xx unknown
- 2005-02-08 NO NO20050661A patent/NO333458B1/no not_active IP Right Cessation
- 2005-02-16 HR HRP20050149AA patent/HRP20050149B1/hr not_active IP Right Cessation
- 2005-02-18 IS IS7701A patent/IS2878B/is unknown
-
2006
- 2006-06-14 US US11/452,782 patent/US7550445B2/en not_active Expired - Fee Related
-
2009
- 2009-04-02 US US12/417,067 patent/US20090186903A1/en not_active Abandoned
- 2009-07-07 CY CY20091100712T patent/CY1110331T1/el unknown
-
2011
- 2011-03-11 US US13/046,124 patent/US20110160224A1/en not_active Abandoned
- 2011-11-03 US US13/288,077 patent/US20120053145A1/en not_active Abandoned
-
2012
- 2012-10-22 US US13/656,785 patent/US20130045981A1/en not_active Abandoned
-
2013
- 2013-04-29 US US13/872,517 patent/US8999952B2/en not_active Expired - Fee Related
-
2015
- 2015-03-03 US US14/636,283 patent/US20150328335A1/en not_active Abandoned
- 2015-09-28 AR ARP150103114A patent/AR102101A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040887A1 (es) | Formulacion y metodo de complejo de aripiprazol | |
| ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
| AR054227A1 (es) | Composicion de principios activos | |
| AR032204A1 (es) | Complejos de inclusion de ciclodextrina-drospirenona | |
| CR8181A (es) | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| MX2009009463A (es) | Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo. | |
| CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
| CL2008003305A1 (es) | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. | |
| BR112012022797A2 (pt) | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool | |
| CR9933A (es) | Agentes que se enlazan con un objetivo en el tejido pulmonar para el tratamiento de enfermedades respiratorias | |
| BR0112311A (pt) | Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso | |
| PA8586201A1 (es) | Nuevas formulaciones de liberacion prolongada inyectables | |
| AR034900A1 (es) | Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica | |
| AR059843A1 (es) | Nuevas composiciones topicas en forma de emulsion ac/ag que comprenden un glicol propenetrante | |
| RS50832B (sr) | Agens oleogela sa sadržajem triterpena, oleogel sa sadržajem triterpena i postupak za proizvodnju oleogela sa sadržajem triterpena | |
| BRPI0415986A (pt) | método e aparelho para reduzir a incidência do uso de tabaco | |
| BRPI0606528A2 (pt) | composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma | |
| BRPI0506630A (pt) | composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada | |
| AR029092A1 (es) | Composiciones para el tratamiento del cabello | |
| SV2003001098A (es) | Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion | |
| NO20091517L (no) | Emulsjon | |
| AR030140A1 (es) | Composiciones derivadas de la 2-piridinamina y metodos relacionados | |
| BR0116152B1 (pt) | aditivo adequado para uso como emulsificador e solubilizador, uso de um aditivo, e, composição. | |
| WO2008027796A3 (en) | Compositions and methods for treating or preventing glaucoma or progression thereof | |
| CL2008003558A1 (es) | Composicion farmaceutica que comprende valrubicina y sulfoxido de dimetilo en forma de dosis intravesical, util para tratar cancer a la vejiga. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |